reptides › focus › mots-c

mots-c

mitochondrial peptide your body makes during exercise. restores metabolic health in mice. human trials just starting.

tier B · focus · 16 aa mitochondrial-derived

verdict

a mitochondrial-derived peptide. AMPK activation, mouse data is strong and replicated. the first-in-human parent-molecule trial just started April 2026.

if you're asking whether MOTS-c works in humans yet — registered, not completed. NCT07505745 (insulin sensitivity in adults) was posted April 1, 2026 and is recruiting as a phase 2a. that ends the 'zero human trial' framing. it does not close the evidence gap. the closest prior human data is CB4211, a synthetic analog with different pharmacokinetics, in 20 NAFLD patients for 4 weeks.

if you're asking about the AMPK / mitochondrial biology — in mice, the effect is real and replicated. activates AMPK via the AICAR pathway, improves insulin sensitivity, glucose tolerance, and exercise capacity. levels rise with exercise, fall roughly 50% between young and old mice. three injections a week restore treadmill performance and metabolic flexibility in aged mice (22-23 months). a 2025 Experimental and Molecular Medicine paper extended the mechanism into pancreatic islet senescence and T2D delay.

if you came in via the longevity / metabolic-health framing — cross-sectional human studies show exercise raises endogenous MOTS-c. that's biomarker movement, not therapeutic outcome. mitochondria weren't known to make signaling peptides until this one, and the mechanism is unusually well-characterized for an unapproved compound. interesting science, finally in humans, still unproven as a therapy.

based on published evidence and disclosed clinical practice. not medical advice.

why B-tier

B-tier because the preclinical evidence is genuinely novel and interesting (mitochondrial-encoded peptide, exercise-induced, age-declining, aging-reversing in mice), but parent-molecule human results have not read out. Not C-tier because the mechanism is well-characterized and the animal data is extensive. Not A-tier because the jump from mouse to human requires completed clinical testing. MOTS-c sits in an unusual category: exceptional biology, early human development.

the core tension

MOTS-c is encoded in the mitochondrial genome, not the nuclear one. that alone is rare. it's exercise-induced, age-declining, and restoring it in aged mice rebuilds metabolic function and exercise capacity. the preclinical case is strong. a first-in-human trial is finally recruiting, but no human efficacy result has read out. translation is still mouse pharmacology plus mechanism plus a trial finally beginning.

what it is

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome, within the 12S rRNA region. discovered in 2015 at USC's Leonard Davis School of Gerontology by Pinchas Cohen and Changhan Lee. it acts as a retrograde signal from mitochondria to nucleus, shifting gene expression around metabolism and stress.

what it does

improves insulin sensitivity, glucose tolerance, and exercise capacity in mice. activates AMPK via the AICAR pathway. levels rise with exercise, fall roughly 50% between young and old mice. in aged mice (22-23 months), three injections a week restore treadmill performance and metabolic flexibility.

origin

characterized at USC from 2015. original paper in Cell Metabolism, follow-ups in Nature Communications. CohBar built an analog called CB4211 and ran phase 1a/1b in NAFLD patients in 2021 with positive ALT/AST/glucose signals. CohBar wound down in 2023. phase 2 never ran.

why researchers are interested

the biology is novel. mitochondria were not known to make signaling peptides until this one. exercise-induced, age-declining, rejuvenating in aged mice. the mechanism (cardiolipin-adjacent stress signaling, AMPK activation, retrograde transcription) is unusually well-characterized for an unapproved compound.

does it work

in mice, the effect is real and replicated. the first-in-human parent-molecule trial (NCT07505745, insulin sensitivity in adults) was posted April 1, 2026 and is recruiting as a phase 2a. that ends the 'zero human trial' framing. it does not close the evidence gap. registered is not completed. until that reads out, the closest human data is CB4211, a synthetic analog with different pharmacokinetics, in 20 NAFLD patients for 4 weeks. a 2025 Experimental and Molecular Medicine paper (PMID 40855115) extended the mechanism into pancreatic islet senescence and T2D delay, still mouse. cross-sectional human studies show exercise raises endogenous MOTS-c, but that's biomarker movement, not therapeutic outcome. interesting science, finally in humans, still unproven as a therapy.

claims vs the data

  • regulates glucose uptake and insulin sensitivity — supported — Multiple preclinical studies in mouse models of diet-induced obesity and T2D show improved glucose tolerance and insulin sensitivity with MOTS-c administration. Original Cohen/Lee 2015 Cell Metabolism paper and follow-up work.
  • enhances exercise capacity and physical performance — partially true — Documented in young, middle-aged, and old mice across multiple studies. Effects are real in rodents. A first-in-human MOTS-c trial is registered, but parent-molecule human results are still pending.
  • reverses aspects of metabolic aging — partially true — Late-life (23.5 month) mouse studies show restored treadmill performance and improved metabolic markers. Impressive preclinical aging-reversal signal. Whether this translates to human aging is open.
  • exercise-induced mitochondrial peptide — supported — MOTS-c levels increase with exercise in mice and in human subjects. One of the clearer signals establishing it as a legitimate exercise-response signaling molecule.
  • activates AMPK via the AICAR pathway — supported — Mechanism characterized at the molecular level. Provides a distinct pharmacological route to AMPK activation compared to direct activators or metformin's pathway.
  • proven to extend healthspan in humans — contradicted — MOTS-c itself has never completed a human clinical trial. The closest human data is CohBar's CB4211 (2021 Phase 1a/1b), a MOTS-c analog, not MOTS-c itself, which showed positive metabolic markers (ALT, AST, glucose reduced vs placebo) in 20 NAFLD patients after 4 weeks. CohBar wound down in 2023; Phase 2 never ran. Community claims of 'aging reversal' extrapolate from mouse longevity data and outrun the clinical evidence substantially.

key facts

  • molecular formula: C101H152N28O22S2
  • molecular weight: 2174.6 Da
  • amino acids: 16
  • half-life: minutes in plasma; functional effects persist hours via downstream gene expression
  • type: mitochondrial-derived peptide (MDP)
  • CAS: 1627580-64-6
  • 2015 year of discovery (Lee & Cohen)
  • 16 amino acids; encoded in mtDNA
  • 0 complete / 1 recruiting human MOTS-c trials
  • ~50% decline in plasma MOTS-c between young and old mice

frequently asked questions

What is MOTS-c?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene of mitochondrial DNA. Among the first discovered mitochondrial-derived peptides with systemic signaling functions, a newer class of peptides that communicate from mitochondria to the rest of the body.

What does MOTS-c do?

Preclinical and endogenous human biomarker data suggest metabolic biology: insulin sensitivity, AMPK signaling, exercise response, and mitochondrial stress signaling. Parent-molecule treatment data in humans has not read out.

How is MOTS-c typically administered?

There is no FDA-approved administration protocol. Community dosing conventions are not clinically validated, and the first parent-molecule human trial is registered but not completed.

What are the side effects of MOTS-c?

Community and preliminary clinical reports are generally clean. Occasional injection-site reactions. Because formal human clinical trials are limited and long-term use in healthy adults hasn't been systematically characterized, the long-term safety profile remains under investigation.

Is MOTS-c FDA approved?

No. MOTS-c has no FDA approval. It is in early clinical investigation for metabolic indications but has not reached registrational trials or drug-approval status. For sport, WADA lists MOTS-c under S4.4.1 metabolic modulators, prohibited at all times.

How much does MOTS-c cost?

No clinical retail price. On the research-chemical market it tends to price higher than simpler peptides, reflecting the synthesis complexity of the 16-amino-acid peptide.

related peptides

  • ss-31 — other major mitochondrial peptide, FDA-approved mechanism vs MOTS-c preclinical
  • NAD+ — companion mitochondrial/metabolic target; often stacked in longevity protocols
  • tesamorelin — metabolic/visceral fat drug, different mechanism, same clinical interest

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.